Trial Profile

An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EVO 756 (Primary)
Indications Chronic urticaria; Cold Urticaria; Familial dermographism
Focus Adverse reactions
Sponsors Evommune

Most Recent Events

18 Jun 2025 Status changed from active, no longer recruiting to completed.
28 May 2025 According to an Evommune media release, data from this trial support ongoing development of EVO756 in Phase 2b trials in Chronic Spontaneous Urticaria and Atopic Dermatitis. Full data set expected to be presented at upcoming medical meeting in second half of 2025
28 May 2025 Results presented in the Evommune media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com